JP2022523368A - １－（１－オキソ－１，２－ジヒドロイソキノリン－５－イル）－５－（トリフルオロメチル）－ｎ－［２－（トリフルオロメチル）ピリジン－４－イル］－１ｈ－ピラゾール－４－カルボキサミド一水和物の結晶形態 - Google Patents

１－（１－オキソ－１，２－ジヒドロイソキノリン－５－イル）－５－（トリフルオロメチル）－ｎ－［２－（トリフルオロメチル）ピリジン－４－イル］－１ｈ－ピラゾール－４－カルボキサミド一水和物の結晶形態 Download PDF

Info

Publication number
JP2022523368A
JP2022523368A JP2021549407A JP2021549407A JP2022523368A JP 2022523368 A JP2022523368 A JP 2022523368A JP 2021549407 A JP2021549407 A JP 2021549407A JP 2021549407 A JP2021549407 A JP 2021549407A JP 2022523368 A JP2022523368 A JP 2022523368A
Authority
JP
Japan
Prior art keywords
compound
weight
cancer
disease
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021549407A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020169736A5 (enExample
Inventor
レイス，カリナ
キンペ，クリストフ，レオナルド
ガートマン，ロバート，マイケル
ウェイ，ハオジュアン
ジョウ，ペン
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2022523368A publication Critical patent/JP2022523368A/ja
Publication of JPWO2020169736A5 publication Critical patent/JPWO2020169736A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021549407A 2019-02-22 2020-02-20 １－（１－オキソ－１，２－ジヒドロイソキノリン－５－イル）－５－（トリフルオロメチル）－ｎ－［２－（トリフルオロメチル）ピリジン－４－イル］－１ｈ－ピラゾール－４－カルボキサミド一水和物の結晶形態 Pending JP2022523368A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019075834 2019-02-22
CNPCT/CN2019/075834 2019-02-22
PCT/EP2020/054485 WO2020169736A1 (en) 2019-02-22 2020-02-20 Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate

Publications (2)

Publication Number Publication Date
JP2022523368A true JP2022523368A (ja) 2022-04-22
JPWO2020169736A5 JPWO2020169736A5 (enExample) 2023-02-28

Family

ID=69723907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549407A Pending JP2022523368A (ja) 2019-02-22 2020-02-20 １－（１－オキソ－１，２－ジヒドロイソキノリン－５－イル）－５－（トリフルオロメチル）－ｎ－［２－（トリフルオロメチル）ピリジン－４－イル］－１ｈ－ピラゾール－４－カルボキサミド一水和物の結晶形態

Country Status (21)

Country Link
US (1) US12269813B2 (enExample)
EP (1) EP3927696B1 (enExample)
JP (1) JP2022523368A (enExample)
KR (1) KR20210131371A (enExample)
CN (1) CN113474339B (enExample)
AU (1) AU2020226723B2 (enExample)
BR (1) BR112021016400A2 (enExample)
CA (1) CA3129623A1 (enExample)
EA (1) EA202192320A1 (enExample)
EC (1) ECSP21067828A (enExample)
ES (1) ES2966132T3 (enExample)
IL (1) IL285675A (enExample)
JO (1) JOP20210227A1 (enExample)
MA (1) MA55019A (enExample)
MX (1) MX2021010133A (enExample)
PE (1) PE20212067A1 (enExample)
PH (1) PH12021552018A1 (enExample)
SG (1) SG11202108909SA (enExample)
TW (1) TW202045495A (enExample)
UY (1) UY38592A (enExample)
WO (1) WO2020169736A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
BR112023003106A2 (pt) 2020-08-21 2023-04-04 Janssen Pharmaceutica Nv Forma amorfa de um inibidor de malt1 e formulações do mesmo
BR112023017689A2 (pt) 2021-03-03 2023-11-14 Janssen Pharmaceutica Nv Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n­(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida)
EP4301365A1 (en) 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Combination therapy using a malt1 inhibitor and a btk inhibitor
AU2022326183A1 (en) * 2021-08-09 2024-03-28 Janssen Pharmaceutica Nv Compositions for use in treating b-cell malignancies
WO2025073968A1 (en) 2023-10-06 2025-04-10 Ionctura Sa Combination of roginolisib with a malt1-gls inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180170909A1 (en) * 2016-12-21 2018-06-21 Janssen Biotech, Inc. Pyrazole derivatives as malt1 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525183A (ja) 2003-04-30 2007-09-06 アジェンシス， インコーポレイテッド 癌の処置および検出において有用な１０９ｐ１ｄ４と称される、核酸および対応タンパク質
WO2007111904A2 (en) * 2006-03-22 2007-10-04 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
WO2008092292A1 (en) 2007-01-17 2008-08-07 The Hong Kong University Of Science And Technology Isoquinolone compounds as subtype-selective agonists for melatonin receptors mt1 and mt2
WO2011036885A1 (ja) * 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
KR101580714B1 (ko) 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
CN102947270B (zh) 2010-06-22 2015-04-08 巴斯夫欧洲公司 制备4-羟基吡啶的方法
MX2014014531A (es) * 2012-05-31 2015-04-08 Hoffmann La Roche Derivados de aminoquinazolina y piridopirimidina.
HUE044351T2 (hu) 2014-05-28 2019-10-28 Novartis Ag Új pirazolo-pirimidin származékok és azok alkalmazása MALT1 inhibitorként
EP3177366A4 (en) 2014-08-08 2018-04-04 Pharmacyclics LLC Bruton's tyrosine kinase inhibitor combinations and uses thereof
US10835524B2 (en) * 2015-06-24 2020-11-17 University Of Florida Research Foundation, Incorporated Compositions for the treatment of pancreatic cancer and uses thereof
CA3003820A1 (en) 2015-11-13 2017-05-18 Novartis Ag Novel pyrazolo pyrimidine derivatives
EP3423452B1 (en) 2016-03-01 2025-05-07 University of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
EP3576744A1 (en) 2017-02-01 2019-12-11 Medivir Aktiebolag Therapeutic applications of malt1 inhibitors
US11571427B2 (en) 2017-12-28 2023-02-07 The General Hospital Corporation Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment
WO2019161921A1 (de) 2018-02-23 2019-08-29 Industrieanlagen-Betriebsgesellschaft Mbh Vorrichtung zum erzeugen eines magnetfelds, insbesondere für ein induktives ladesystem, und primäreinrichtung eines induktiven ladesystems zum dynamischen aufladen von fahrzeugen
WO2021138298A1 (en) 2019-12-30 2021-07-08 Rheos Medicines, Inc. Malt1 modulators and uses thereof
BR112023003106A2 (pt) * 2020-08-21 2023-04-04 Janssen Pharmaceutica Nv Forma amorfa de um inibidor de malt1 e formulações do mesmo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180170909A1 (en) * 2016-12-21 2018-06-21 Janssen Biotech, Inc. Pyrazole derivatives as malt1 inhibitors

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"医薬品の塩選択，結晶多形のスクリーニングの重要性について", 薬剤学, vol. 第66巻、第6号, JPN6024037935, 2006, pages 435 - 439, ISSN: 0005426144 *
"医薬品開発における結晶形選択の効率化を目指して", 薬剤学, vol. 68巻5号, JPN6024037937, 2008, pages 344 - 349, ISSN: 0005426146 *
"製剤化のための最適な原薬の結晶形態の設計", 化学工学会 研究発表講演要旨集, JPN6024037936, 2010, pages 436 - 437, ISSN: 0005426145 *
JOURNAL OF MEDICINE, vol. 19, no. 2, JPN6008003682, 1988, US, pages 109 - 117, ISSN: 0005248891 *
ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 2009, Vol.13, No.6, JPN6020035450, pages 1241 - 1253, ISSN: 0005426140 *
平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005426141 *
社団法人日本化学会編, 第４版実験化学講座１基本操作Ｉ, vol. 第１８４−１８９頁, JPN7008003682, 5 April 1996 (1996-04-05), ISSN: 0005426142 *
第十六改正 日本薬局方, JPN6014035187, 2011, pages 64 - 68, ISSN: 0005285936 *
芦澤 一英: "塩・結晶形の最適化と結晶化技術", PHARM TECH JAPAN, vol. 18, no. 10, JPN6013060608, 2002, pages 81 - 96, ISSN: 0005426143 *

Also Published As

Publication number Publication date
CN113474339A (zh) 2021-10-01
US20220127249A1 (en) 2022-04-28
CA3129623A1 (en) 2020-08-27
EP3927696A1 (en) 2021-12-29
PH12021552018A1 (en) 2022-09-19
JOP20210227A1 (ar) 2023-01-30
IL285675A (en) 2021-10-31
WO2020169736A1 (en) 2020-08-27
TW202045495A (zh) 2020-12-16
ECSP21067828A (es) 2021-11-18
AU2020226723B2 (en) 2025-01-23
UY38592A (es) 2020-08-31
CN113474339B (zh) 2025-02-25
SG11202108909SA (en) 2021-09-29
AU2020226723A1 (en) 2021-08-19
PE20212067A1 (es) 2021-10-26
ES2966132T3 (es) 2024-04-18
MX2021010133A (es) 2021-09-23
EP3927696B1 (en) 2023-10-18
EA202192320A1 (ru) 2021-11-16
MA55019A (fr) 2021-12-29
US12269813B2 (en) 2025-04-08
KR20210131371A (ko) 2021-11-02
BR112021016400A2 (pt) 2021-10-13
EP3927696C0 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
JP2022523368A (ja) １－（１－オキソ－１，２－ジヒドロイソキノリン－５－イル）－５－（トリフルオロメチル）－ｎ－［２－（トリフルオロメチル）ピリジン－４－イル］－１ｈ－ピラゾール－４－カルボキサミド一水和物の結晶形態
AU2019392683B2 (en) Combination therapies
JP2022105141A (ja) エフェクターｔ細胞機能を増進するための、セレブロンを標的とする小分子
WO2020055755A1 (en) Combination therapies
KR20250005505A (ko) 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
WO2023059598A1 (en) Combination therapies of kras g12d inhibitors with shp-2 inhibitors
CN113454081A (zh) 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途
KR20200144579A (ko) 피리미딘 유도체의 약학 염 및 장애의 치료 방법
WO2021017384A1 (zh) 二氢吡咯并嘧啶类选择性jak2抑制剂
EP2646427A1 (en) Quinolin-4 (1h) -one derivatives as inhibitors of phosphatidylinositol 3-kinases
CN110049976A (zh) 布鲁顿氏酪氨酸激酶抑制剂的琥珀酸盐形式和组合物
TWI796250B (zh) 經取代之 5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式
KR20140040671A (ko) 아프레피탄트 l-프롤린 조성물 및 공결정
JP7712994B2 (ja) 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
CN101993417A (zh) 磷酸二甲啡烷的稳定新晶型
CN111662275A (zh) 苯磺酰胺类idh突变体抑制剂、其制备方法和用途
EA045924B1 (ru) Кристаллическая форма моногидрата 1-(1-оксо-1,2-дигидроизохинолин-5-ил)-5-(трифторметил)-n-(2-(трифторметил)пиридин-4-ил)-1h-пиразол-4-карбоксамида
HK40052643A (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
JP2021527120A (ja) 塩形態
JP2021527119A (ja) 塩形態
TW201829398A (zh) 酪胺酸蛋白激酶調節劑、晶型及其用途
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
HK40072166B (zh) 杂环化合物及其制备方法和用途
HK40058867A (en) Imidazopyridinyl compounds and use thereof for treatment of proliferative disorders
HK1261832B (zh) 喹唑啉衍生物的盐的晶体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240619

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241001